Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs78378222
rs78378222
G 0.720 GeneticVariation GWASCAT Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. 29743610

2018

dbSNP: rs78378222
rs78378222
G 0.720 GeneticVariation GWASCAT Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. 28346443

2017

dbSNP: rs78378222
rs78378222
0.720 GeneticVariation BEFREE As rs78378222 changes the polyadenylation signal of TP53 leading to impaired 3'-end processing of TP53 mRNA, the SNP has strong plausibility for being directly functional contributing to the aetiological basis of glioma. 23571737

2013

dbSNP: rs78378222
rs78378222
0.720 GeneticVariation BEFREE The rs78378222 SNP is the first confirmed rare susceptibility variant in glioma. 22706378

2012

dbSNP: rs35850753
rs35850753
T 0.700 GeneticVariation GWASCAT Genome-wide association study identifies multiple susceptibility loci for glioma. 26424050

2015

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE These findings suggest that the pri-miR-34b/c rs4938723CC and TP53 Arg72-Pro polymorphisms may be associated with the risk of glioma. 30319976

2018

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE Thus, there is limited evidence for the association between the</span> TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians. 24046089

2014

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk. 24488625

2014

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian. 23860773

2013

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma. 23096687

2012

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE The codon 72 variant (rs1042522) and rs1642785 polymorphisms possibly poses risk to glioma development in Indian population. 21115003

2011

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy. 18068527

2008

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE Our data suggest that TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival, at least in the Brazilian population. 18393224

2008

dbSNP: rs55819519
rs55819519
0.070 GeneticVariation BEFREE IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. 30760578

2019

dbSNP: rs1131691014
rs1131691014
0.070 GeneticVariation BEFREE These findings suggest that the pri-miR-34b/c rs4938723CC and TP53 Arg72-Pro polymorphisms may be associated with the risk of glioma. 30319976

2018

dbSNP: rs878854066
rs878854066
0.070 GeneticVariation BEFREE These findings suggest that the pri-miR-34b/c rs4938723CC and TP53 Arg72-Pro polymorphisms may be associated with the risk of glioma. 30319976

2018

dbSNP: rs55819519
rs55819519
0.070 GeneticVariation BEFREE IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. 28427200

2017

dbSNP: rs55819519
rs55819519
0.070 GeneticVariation BEFREE This case suggests that 1p/19q co-deletion may rarely precede IDH1 mutations or that IDH1 mutations may be secondarily lost, as demonstrated by IDH1-R132H positive and negative cells in a glioma with diffuse 1p/19q co-deletion. 25907263

2016

dbSNP: rs1131691014
rs1131691014
0.070 GeneticVariation BEFREE In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk. 24488625

2014

dbSNP: rs1131691014
rs1131691014
0.070 GeneticVariation BEFREE Thus, there is limited evidence for the association between the</span> TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians. 24046089

2014

dbSNP: rs878854066
rs878854066
0.070 GeneticVariation BEFREE Thus, there is limited evidence for the association between the</span> TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians. 24046089

2014

dbSNP: rs878854066
rs878854066
0.070 GeneticVariation BEFREE In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk. 24488625

2014

dbSNP: rs1131691014
rs1131691014
0.070 GeneticVariation BEFREE In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian. 23860773

2013

dbSNP: rs55819519
rs55819519
0.070 GeneticVariation BEFREE Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. 23934175

2013

dbSNP: rs55819519
rs55819519
0.070 GeneticVariation BEFREE This study analyses a series of 184 glioma cases in a tissue microarray (TMA)-based approach to assess the frequency of R132H point mutations in formalin-fixed, paraffin-embedded tissue samples. 23361281

2013